Systemic hypermetabolism could be a modifier of disease progression in patients with amyotrophic lateral sclerosis (ALS). Plasma lipidomic analysis could potentially be used to stratify patients with ALS.
Why this matters
ALS is a clinically heterogeneous neurodegenerative disease. It is known that metabolic changes, specifically hypermetabolism, have a significant bearing on prognosis in patients with ALS.
The results of lipid profiling using liquid chromatography with mass spectrometry (LC/MS) have been published for select ALS cases. Lipid profiles have either been performed for the cerebrospinal fluid (CFS) or plasma, but never in the same patient.